COMMUNIQUÉS West-GlobeNewswire

-
Kaida BioPharma Chairman and Founding Investor, Craig Pierson, to Present at Opal Group’s Family Office & Private Wealth Management Forum 2025
21/07/2025 -
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
21/07/2025 -
VitalHub Announces Q2 2025 Conference Call Date
21/07/2025 -
Spirair Receives FDA Clearance for TurbAlign, a New Bioabsorbable Implant That Helps Keep Nasal Passages Open After Sinus Surgery
21/07/2025 -
Sharecare introduces Condition Masterclass to support patient education and health literacy for chronic disease management
21/07/2025 -
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
21/07/2025 -
Veteran Global Health Leader, Dr. Rebecca Martin, Named President of Global Immunization at Sabin
21/07/2025 -
Acentra Health Names Marnie Keogh as Senior Vice President of Marketing
21/07/2025 -
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
21/07/2025 -
Foundation for Sarcoidosis Research Sarc Fighter Podcast Surpasses 100,000 Downloads, Amplifying Voices in the Sarcoidosis Community
21/07/2025 -
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
21/07/2025 -
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
21/07/2025 -
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
21/07/2025 -
Cannara Biotech Inc. annoncera ses résultats financiers du troisième trimestre de l'exercice 2025 le 28 juillet 2025
21/07/2025 -
Cannara Biotech Inc. to Announce Fiscal Q3 2025 Financial Results on July 28, 2025
21/07/2025 -
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
21/07/2025 -
NewGen Subsidiary Signs Memorandum of Understanding with Prominent UAE Real Estate Developer
21/07/2025 -
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
21/07/2025 -
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
21/07/2025
Pages